{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:05:11Z","timestamp":1777467911160,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BD"],"published-print":{"date-parts":[[2021,6,25]]},"abstract":"<jats:p>BACKGROUND: Increased plasma aldehyde dehydrogenase\u00a01 (ALDH1) levels have been proposed to predict cancer chemoresistance. However, studies have reported inconsistent results, depending on the type of cancer cells used. OBJECTIVE: This study aimed to investigate the correlation between plasma levels of ALDH1 and chemotherapy responses to the taxane\u2013adriamycin\u2013cyclophosphamide (TAC) regimen in breast cancer patients. METHODS: Thirty breast cancer patients who underwent chemotherapy using the TAC regimen were included in this study. Blood sampling was performed before chemotherapy was initiated and after the first and third cycles of chemotherapy administration. After 3 cycles of chemotherapy, patients were categorized as non-responsive if the tumor size was reduced &lt;30%, if the tumor size remained the same or increased, or if any new tumors were discovered. Patients were defined as responsive after 3 cycles of chemotherapy if the tumor mass disappeared, if the tumor size was reduced by at least 30% of the initial size and if no new tumors were found. RESULTS: Among the 30 patients, only five were responsive to the TAC regimen. The clinical response to TAC was not correlated with the patient\u2019s age, cancer grading, or tumor stage. A change in the ALDH1 levels was observed after the third cycle of TAC administration, with significantly higher ALDH1 levels observed in responsive compared with non-responsive patients (p &lt;\u00a00.05). CONCLUSION: The results of this study may indicate a role for ALDH1 in chemoresponsiveness, rather than chemoresistance, for the TAC regimen in breast cancer patients. Further research remains necessary to confirm this result.<\/jats:p>","DOI":"10.3233\/bd-219005","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T13:17:33Z","timestamp":1622207853000},"page":"S33-S37","source":"Crossref","is-referenced-by-count":3,"title":["Increased aldehyde dehydrogenase\u00a01 (ALDH1) levels are associated with chemo-responsiveness in breast cancer patients treated with taxane\u2013adriamycin\u2013cyclophosphamide regimen"],"prefix":"10.1177","volume":"40","author":[{"given":"Hapidah","family":"Hapidah","sequence":"first","affiliation":[{"name":", Hasanuddin University, , Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia Yusrini","family":"Djabir","sequence":"additional","affiliation":[{"name":", , Hasanuddin University, , Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prihantono","family":"Prihantono","sequence":"additional","affiliation":[{"name":", , Hasanuddin University, , Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/BD-219005_ref1","first-page":"43","article-title":"American cancer society\/American society of clinical oncology breast cancer survivorship care guideline","volume":"66","author":"Runowicz","year":"2016","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.3233\/BD-219005_ref2","first-page":"52","article-title":"Neoadjuvant chemotherapy considerations in triple-negative breast cancer","volume":"7","author":"McAndrew","year":"2018","journal-title":"The Journal of Targeted Therapies in Cancer"},{"key":"10.3233\/BD-219005_ref3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3747\/co.v17i1.445","article-title":"Cost effectiveness of tac versus fac in adjuvant treatment of node-positive breast cancer","volume":"17","author":"Mittmann","year":"2010","journal-title":"Current Oncology"},{"key":"10.3233\/BD-219005_ref4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.stem.2012.05.007","article-title":"Cancer stem cells: Current status and evolving complexities","volume":"10","author":"Visvader","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.3233\/BD-219005_ref5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.stem.2009.02.003","article-title":"Cancer stem cells: Controversial or just misunderstood?","volume":"4","author":"Jordan","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.3233\/BD-219005_ref6","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.3233\/BD-219005_ref7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/17425255.4.6.697","article-title":"Non-p450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily","volume":"4","author":"Marchitti","year":"2008","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.3233\/BD-219005_ref8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/modpathol.2009.35","article-title":"Aldh1 expression correlates with favorable prognosis in ovarian cancers","volume":"22","author":"Chang","year":"2009","journal-title":"Modern Pathology"},{"key":"10.3233\/BD-219005_ref9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.biopha.2013.04.005","article-title":"The role of aldehyde dehydrogenase (aldh) in cancer drug resistance","volume":"67","author":"Januchowski","year":"2013","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.3233\/BD-219005_ref10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.prp.2015.05.011","article-title":"The clinicopathological and prognostic significance of cd24, cd44, cd133, aldh1 expressions in invasive ductal carcinoma of the breast: Cd44\/cd24 expression in breast cancer","volume":"211","author":"Kapucuog\u0306lu","year":"2018","journal-title":"Pathology - Research and Practice"},{"key":"10.3233\/BD-219005_ref11","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.clbc.2013.12.006","article-title":"Aldehyde dehydrogenase\u00a01 expression in inflammatory breast cancer as measured by immunohistochemical staining","volume":"14","author":"Gong","year":"2018","journal-title":"Clinical Breast Cancer"},{"key":"10.3233\/BD-219005_ref12","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/bjc.2011.159","article-title":"An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer","volume":"104","author":"Lee","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.3233\/BD-219005_ref13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-016-3738-7","article-title":"Effect of aldh1 on prognosis and chemoresistance by breast cancer subtype","volume":"156","author":"Kida","year":"2016","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.3233\/BD-219005_ref14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"Recist 1.1-update and clarification: from the recist committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"European Journal of Cancer"},{"key":"10.3233\/BD-219005_ref15","doi-asserted-by":"crossref","first-page":"5416923","DOI":"10.1155\/2018\/5416923","article-title":"Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells International"},{"key":"10.3233\/BD-219005_ref16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jso.10090","article-title":"Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer","volume":"80","author":"Gajdos","year":"2002","journal-title":"Journal of Surgical Oncology"},{"key":"10.3233\/BD-219005_ref17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.molonc.2013.10.007","article-title":"Aldh-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients","volume":"8","author":"Ajani","year":"2014","journal-title":"Molecular Oncology"}],"container-title":["Breast Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/BD-219005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:32:12Z","timestamp":1777383132000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/BD-219005"}},"subtitle":[],"editor":[{"given":"Andi Nilawati","family":"Usman","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":17,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/bd-219005","relation":{},"ISSN":["0888-6008","1558-1551"],"issn-type":[{"value":"0888-6008","type":"print"},{"value":"1558-1551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]}}}